Quantitative kinetics of development of N-2-fluorenylacetamide-induced, altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion or persistence following removal of carcinogen

Journal of the National Cancer Institute
G M Williams, K Watanabe

Abstract

For study of the behavior of previously described carcinogen-induced foci of hepatocytes refractory to iron accumulation, iron deposition was induced in all hepatocytes of rat livers by feeding 8-hydroxyquinoline and ferrous gluconate to the animals for 3 months. The kinetics of development of the altered foci of hepatocytes free of stainable iron was then quantified for each lobe of liver for as long as 13 weeks of feeding of the carcinogen N-2-fluorenylacetamide and for 6 months following cessation of carcinogen exposure. The foci increased slowly in number and size for the first 12 weeks of carcinogen administration and then grew rapidly between weeks 12 and 13. At week 13, they corresponded to altered foci that have been observed in sections stained with hematoxylin and eosin, and they also displayed abnormal glycogen storage. After the carcinogen was discontinued, the foci disappeared by a reversion back to iron storage while temporarily retaining the nuclear abnormalities of altered cells. Over 95% of altered foci at this stage underwent reversion by 6 months following removal of the carcinogen. More advanced lesions developed in the lobes that displayed the greatest incidence and persistence of foci.

Citations

Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·K Aterman
Jan 1, 1989·Toxicologic Pathology·James A Popp, T L Goldsworthy
Jan 1, 1989·European Journal of Clinical Pharmacology·D W KaufmanS Shapiro
Jan 1, 1986·Critical Reviews in Toxicology·T L GoldsworthyH C Pitot
May 11, 2002·Current Hypertension Reports·E GrossmanU Goldbourt
Oct 27, 2004·Toxicologic Pathology·Gary M WilliamsAlan M Jeffrey
Nov 28, 2007·Annual Review of Pathology·H C Pitot
Jan 1, 1983·Annals of the New York Academy of Sciences·R Kroes
Apr 15, 1982·International Journal of Cancer. Journal International Du Cancer·S TakahashiH Shinozuka
Feb 1, 1982·Toxicologic Pathology·Paul M NewberneAnthony J Clark
Dec 1, 1985·Toxicology and Industrial Health·M A Pereira
Jan 1, 1993·Toxicologic Pathology·G ScampiniG Mazué
Mar 1, 1987·Toxicology and Industrial Health·E RindeB Haberman
Sep 12, 2000·Current Hypertension Reports·E GrossmanU Goldbourt
Dec 20, 2007·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Gary M WilliamsCarmen E Perrone
Apr 1, 1983·Environmental Health Perspectives·G M Williams
Jan 1, 1982·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S Sell, H L Leffert
Jan 1, 1988·Journal of Cancer Research and Clinical Oncology·H Enzmann, Peter Bannasch
May 25, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kang-Sik ParkYoung-Ki Paik
Feb 1, 1982·Toxicologic Pathology·Peter BannaschHeide Zerban
May 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·B E HuberS S Thorgeirsson

Related Concepts

Metazoa
Cell Nucleolus
Cell Nucleus
Fluorenes
Hyperplasia
Iron
Liver
Liver Glycogen
Malignant Neoplasm of Liver
Condition, Preneoplastic

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.